Sun Fujing, Gao Xiaozhuo, Li Tianming, Zhao Xiaoyan, Zhu Yanmei
Department of Pathology, Affiliated Cancer Hospital of Dalian University of Technology (Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University), Shenyang, China.
Graduate School, Dalian Medical University, Dalian, China.
Biochim Biophys Acta Rev Cancer. 2025 Jul;1880(3):189350. doi: 10.1016/j.bbcan.2025.189350. Epub 2025 May 10.
Gastric cancer (GC) is a malignant tumor with one of the highest morbidity and death rates in the world. Neoadjuvant therapy, including neoadjuvant chemotherapy (NAC) and NAC combined with immunotherapy, can improve the resection and long-term survival rates. However, not all patients respond well to neoadjuvant therapy. It has been confirmed that immune cells in the tumor immune microenvironment, including T cells, B cells, and natural killer cells, can affect the efficacy of neoadjuvant therapy. This paper summarizes current preclinical and clinical evidence to more fully describe the effects of neoadjuvant therapy on the immune microenvironment of GC, to provide the impetus to identify biomarkers to predict the potency of neoadjuvant therapy, and to identify the mechanisms of drug resistance, which should promote the development of individualized and accurate treatments for GC patients.
胃癌（GC）是一种发病率和死亡率位居世界前列的恶性肿瘤。新辅助治疗，包括新辅助化疗（NAC）以及NAC联合免疫治疗，能够提高切除率和长期生存率。然而，并非所有患者对新辅助治疗都反应良好。已经证实，肿瘤免疫微环境中的免疫细胞，包括T细胞、B细胞和自然杀伤细胞，会影响新辅助治疗的疗效。本文总结了当前的临床前和临床证据，以更全面地描述新辅助治疗对GC免疫微环境的影响，为识别预测新辅助治疗疗效的生物标志物以及确定耐药机制提供动力，这将推动针对GC患者的个体化精准治疗的发展。
